HIV patients treated with low-dose prednisolone exhibit lower immune activation than untreated patients.

ABSTRACT:

Background

HIV-associated general immune activation is a strong predictor for HIV disease progression, suggesting that chronic immune activation may drive HIV pathogenesis. Consequently, immunomodulating agents may decelerate HIV disease progression.

Methods

In an observational study, we determined immune activation in HIV patients receiving low-dose (5 mg/day) prednisolone with or without highly-active antiretroviral therapy (HAART) compared to patients without prednisolone treatment. Lymphocyte activation was determined by flow cytometry detecting expression of CD38 on CD8(+) T cells. The monocyte activation markers sCD14 and LPS binding protein (LBP) as well as inflammation markers soluble urokinase plasminogen activated receptor (suPAR) and sCD40L were determined from pl

SUBMITTER: Kasang C 

PROVIDER: S-EPMC3282641 | biostudies-literature | 2012 Jan

REPOSITORIES: biostudies-literature